Veravas Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Veravas's estimated annual revenue is currently $2.6M per year.(i)
  • Veravas's estimated revenue per employee is $155,000

Employee Data

  • Veravas has 17 Employees.(i)
  • Veravas grew their employee count by -19% last year.

Veravas's People

NameTitleEmail/Phone
1
Founder and CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Principal ScientistReveal Email/Phone
5
Senior Scientific AdvisorReveal Email/Phone
6
Process ScientistReveal Email/Phone
7
Process ScientistReveal Email/Phone
8
Board AdvisorReveal Email/Phone
9
Process ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.8M509%N/AN/A
#2
$7.4M48-35%N/AN/A
#3
$0.9M620%N/AN/A
#4
$0.3M2-91%N/AN/A
#5
$3.6M235%N/AN/A
#6
$0.9M6-33%N/AN/A
#7
$5M323%N/AN/A
#8
$14.7M959%N/AN/A
#9
$14.7M950%$20.5MN/A
#10
$27.9M14413%$39.1MN/A
Add Company

What Is Veravas?

Veravas, Inc. is an early-stage biotechnology company focused on transforming the practice of laboratory medicine with technology that delivers superior test results, providing confidence to clinicians and patients that diagnostic tests when performed are accurate. The company is rapidly driving the commercialization of proprietary sample preparation and sample interference products and development of new diagnostic tests for the IVD marketplace. Veravas is currently developing IVD testing solutions for the COVID-19 market utilizing its proprietary nanobead technology and VeraPrepâ„¢ reagents. To learn more about our technologies and clinical applications, visit veravas.com

keywords:N/A

N/A

Total Funding

17

Number of Employees

$2.6M

Revenue (est)

-19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Veravas News

2022-04-06 - Nanomagnetics Market – Top Companies, Business Growth ...

Veravas's nanomagnetic particles will recognize, eliminate and measure substances from sample of patients to reduce the effects of complex...

2022-03-30 - Investigating Immunoassay Interferences | AACC.org

... such as Scantibodies or Veravas, can be used to remove heterophile antibodies or biotin from the patient sample.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.7M21-22%N/A
#2
$4M21-5%N/A
#3
$2.3M22-4%N/A
#4
$2.7M24-11%N/A
#5
$2.4M24-17%N/A